The Latest News from Vascular Therapies
Vascular Therapies Announces Positive Preliminary Clinical Results from its AV Fistula Trials in Patients with Kidney Disease
CRESSKILL, NJ (Sep. 5, 2019)–Vascular Therapies, a clinical stage biotechnology company, is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local, perivascular drug delivery focused on improving vascular access outcomes in patients with kidney disease. Daniel G. Clair, MD, vascular surgeon and Chairman of the Department of Surgery at Palmetto Health-USC Medical Group in Columbia, South Carolina presented preliminary results from the company’s clinical development program at the recent Eastern Vascular Society Meeting in Pittsburg, Pennsylvania.
Vascular Therapies Announces Completion of Enrollment in the ACCESS Study, a U.S. Phase III Clinical Trial
CRESSKILL, NJ (Aug. 19, 2019)–Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, today announced completion of enrollment in its US Phase III prospective randomized, multicenter, clinical study (ACCESS Trial).
Vascular Therapies Appoints John McDermott as Chief Executive Officer
CRESSKILL, NJ (January 15, 2019) –Vascular Therapies, a biotechnology company focused on improving outcomes for patients with advanced kidney disease today announced the appointment of John McDermott as the Company’s Chief Executive Officer.